Until this year, parathyroid hormone and its related protein analogues were the only recommended anabolic agents for postmenopausal osteoporosis patients with multiple fractures.1 Patients who are contraindicated to the treatment or those who cannot tolerate frequent injections should be switched to

In western countries, psoriatic arthritis (PsA) is observed in about 20–30% of patients with psoriasis.¹ In Hong Kong, the estimated prevalence rate of psoriasis is around 0.3%-0.6% and there was over 20,000 patients suffering from psoriasis as of 2015.²